Merus (NASDAQ: MRUS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update